[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335858-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335858-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-cancer-detection-in-li-fraumeni-syndrome-with-cell-free-dna-research-article","Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA - Research Article","","People with Li–Fraumeni syndrome (LFS) carry germline pathogenic TP53 variants and face near-100% lifetime cancer risk, leading to intensive surveillance. A proof-of-principle multimodal liquid biopsy assay integrates a targeted gene panel, shallow whole-genome analysis, and cell-free methylated DNA immunoprecipitation sequencing in a longitudinal cohort of 89 LFS patients. Multimodal analysis improved cancer detection versus uni-modal approaches and detected cancer-associated signals in carriers before diagnosis, with positive predictive value 67.6% and negative predictive value 96.5%.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-cancer-detection-in-li-fraumeni-syndrome-with-cell-free-dna-research-article/335858/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-cancer-detection-in-li-fraumeni-syndrome-with-cell-free-dna-research-article/335858.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal for Li–Fraumeni syndrome patients?","Question",{"text":63,"@type":64},"To provide a proof-of-principle multimodal liquid biopsy framework for earlier cancer detection in a longitudinal cohort of LFS patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What components are included in the multimodal liquid biopsy assay?",{"text":68,"@type":64},"A targeted gene panel, shallow whole-genome analysis, and cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq).",{"name":70,"@type":61,"acceptedAnswer":71},"How did multimodal analysis perform compared with uni-modal approaches?",{"text":72,"@type":64},"Multimodal analysis increased detection rates in patients with active cancer diagnosis and identified cancer-associated signals in carriers before conventional screening, with PPV 67.6% and NPV 96.5%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335858,1790170929,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","RESEARCH ARTICLE  \nEarly Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA   \nDerek Wong1, Ping Luo1, Leslie E. Oldfield1, Haifan Gong2, Ledia Brunga2, Ron Rabinowicz2,  \nVallijah Subasri2,3,4, Clarissa Chan1, Tiana Downs1, Kirsten M. Farncombe5, Beatrice Luu1, Maia Norman1, Julia A. Sobotka1, Precious Uju1, Jenna Eagles1, Stephanie Pedersen1, Johanna Wellum1, Arnavaz Danesh1, Stephenie D. Prokopec1, Eric Y. Stutheit-Zhao1, Nadia Znassi1, Lawrence E. Heisler6, Richard Jovelin6, Bernard Lam6, Beatriz E. Lujan Toro6, Kayla Marsh6, Yogi Sundaravadanam6, Dax Torti6, Carina Man2, Anna Goldenberg2,4, Wei Xu7, Patrick Veit-Haibach8, Andrea S. Doria2, David Malkin2,3,9, Raymond H. Kim1,2,6, and Trevor J. Pugh1,3,6  \nABSTRACT  People with Li–Fraumeni syndrome (LFS) harbor a germline pathogenic variant in the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and rou  \ntinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multimodal liquid biopsy assay that integrates a targeted gene panel, shallow whole-genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a longitudinal cohort of 89 LFS patients. Multimodal analysis increased our detection rate in patients with an active cancer diagnosis over uni-modal analysis and was able to detect cancer-associated signal(s) in carriers prior to diagnosis with conventional screening (positive predictive value = 67.6%, negative predictive value = 96.5%). Although adoption of liquid biopsy into current surveillance will require further clinical validation, this study provides a framework for individuals with LFS.  \nSIGNIFICANCE: By utilizing an integrated cell-free DNA approach, liquid biopsy shows earlier detection of cancer in patients with LFS compared with current clinical surveillance methods such as imaging. Liquid biopsy provides improved accessibility and sensitivity, complementing current clinical surveillance methods to provide better care for these patients.  \nSee related commentary by Latham et al., p. 23.  \nINTRODUCTION  \nLi–Fraumeni syndrome (LFS; OMIM \\#151623) is a highly penetrant hereditary cancer disorder caused by a pathogenic germline variant in the tumor suppressor gene TP53 (1, 2) . Individuals with∼ germline TP53 mu∼tations have an estimated  \nlifetime risk of 75% in males and 100% in females of developing at least one cancer (3, 4) . The most common cancersin TP53-mutation (TP53m)-carriers are soft-tissue sarcoma, osteosarcoma, brain tumors, breast cancer, and adrenocortical carcinoma (5, 6), although there are a spectrum of additional rare tumors (7) . Approximately 50% of TP53m-carriers will develop multiple cancers (3) with a younger age of diagnosis for the first cancer (8) and previous treatment with radiotherapy (9) as factors contributing to the development of subsequent cancers.  \n1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 2The Hospital for Sick Children, Toronto, Canada. 3Department of Medical Biophysics, University of Toronto, Toronto, Canada. 4Vector Institute, Toronto, Canada. 5Toronto General Hospital Research Institute, Toronto, Canada. 6Ontario Institute for Cancer Research, Toronto, Canada. 7Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. 8Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.  \n9Department of Pediatrics, University of Toronto, Toronto, Canada.  \nD. Wong and P. Luo contributed equally to this article.  \nCorresponding Authors: Trevor J. Pugh, Princess Margaret Cancer Centre, University Health Network, MaRS Centre, 101 College Street, Toronto, Ontario M5G 1L7, Canada. E-mail: [trevor.pugh@utoronto.ca](trevor.pugh@utoronto.ca); Raymond H. Kim, 610 University Avenue, 5th Floor, Tor","cbCaiva6NsbyLmOC","https://ap.wps.com/l/cbCaiva6NsbyLmOC","pdf",14449354,16,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What is the study’s main goal for Li–Fraumeni syndrome patients?\",\"answer\":\"To provide a proof-of-principle multimodal liquid biopsy framework for earlier cancer detection in a longitudinal cohort of LFS patients.\"},{\"question\":\"What components are included in the multimodal liquid biopsy assay?\",\"answer\":\"A targeted gene panel, shallow whole-genome analysis, and cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq).\"},{\"question\":\"How did multimodal analysis perform compared with uni-modal approaches?\",\"answer\":\"Multimodal analysis increased detection rates in patients with active cancer diagnosis and identified cancer-associated signals in carriers before conventional screening, with PPV 67.6% and NPV 96.5%.\"}]","Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA - Research Article | PDF",1790012600]